Mi Helen, MacLaren Robert E, Cehajic-Kapetanovic Jasmina
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Eye (Lond). 2025 Mar;39(4):673-682. doi: 10.1038/s41433-024-03149-3. Epub 2024 Jul 4.
The use of robotic surgery in ophthalmology has been shown to offer many potential advantages to current surgical techniques. Vitreoretinal surgery requires complex manoeuvres and high precision, and this is an area that exceeds manual human dexterity in certain surgical situations. With the advent of advanced therapeutics such as subretinal gene therapy, precise delivery and minimising trauma is imperative to optimize outcomes. There are multiple robotic systems in place for ophthalmology in pre-clinical and clinical use, and the Preceyes Robotic Surgical System (Preceyes BV) has also gained the CE mark and is commercially available for use. Recent in-vivo and in-human surgeries have been performed successfully with robotics systems. This includes membrane peeling, subretinal injections of therapeutics, and retinal vein cannulation. There is huge potential to integrate robotic surgery into mainstream clinical practice. In this review, we summarize the existing systems, and clinical implementation so far, and highlight the future clinical applications for robotic surgery in vitreo-retina.
眼科机器人手术已被证明相对于当前的手术技术具有许多潜在优势。玻璃体视网膜手术需要复杂的操作和高精度，在某些手术情况下，这一领域超出了人类手动操作的灵活性。随着诸如视网膜下基因治疗等先进疗法的出现，精确给药并将创伤降至最低对于优化治疗效果至关重要。有多种机器人系统用于眼科的临床前和临床应用，Preceyes机器人手术系统（Preceyes BV）也已获得CE标志并可商业化使用。最近，机器人系统已成功进行了体内和人体手术。这包括膜剥离、视网膜下治疗药物注射和视网膜静脉插管。将机器人手术整合到主流临床实践中具有巨大潜力。在本综述中，我们总结了现有的系统以及迄今为止的临床应用情况，并强调了机器人手术在玻璃体视网膜领域未来的临床应用。
